2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchMeSH KeywordsAgedCohort StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMedicarePolycythemia VeraRisk FactorsThrombocythemia, EssentialThrombosisUnited StatesConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupSecond malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosis
2022
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds A, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George T, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kaesberg P, Kuykendall A, Madanat Y, McMahon B, Mohan S, Nadiminti K, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein B, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward D, Bergman M, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 1033-1062. PMID: 36075392, DOI: 10.6004/jnccn.2022.0046.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansMedical OncologyMyeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisThrombocythemia, EssentialConceptsNCCN Clinical Practice GuidelinesMyeloproliferative neoplasmsClinical practice guidelinesEssential thrombocythemiaPolycythemia veraRisk stratificationManagement of myeloproliferative neoplasmsOverproduction of blood cellsPhiladelphia chromosome-negative myeloproliferative neoplasmsDiagnosis of myeloproliferative neoplasmsPractice guidelinesClonal blood disorderManagement of myelofibrosisCourse of treatmentSupportive care strategiesAssessment of symptomsNCCN GuidelinesDiagnostic workupCare strategiesMultidisciplinary panelBlood disordersHeterogeneous groupSymptom statusBlood cellsNCCNAnagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database
Rippel N, Tremblay D, Zubizarreta N, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Kremyanskaya M, Hoffman R, Mesa R, Yacoub A, Mascarenhas J. Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leukemia Research 2022, 119: 106903. PMID: 35717689, PMCID: PMC11583043, DOI: 10.1016/j.leukres.2022.106903.Peer-Reviewed Original ResearchMeSH KeywordsCytoreduction Surgical ProceduresHumansPolycythemia VeraQuinazolinesThrombocythemia, EssentialThrombocytosisThrombosisConceptsPolycythemia veraHigh-risk essential thrombocythemiaHigh-risk polycythemia veraLarge multi-centre databaseGuideline-directed managementUse of anagrelideMedian platelet countMulti-center cohortMulti-center databaseVon Willebrand diseaseANA therapyPrior thrombosisTolerability profileCytoreductive agentsMedian durationArterial thrombosesExtreme thrombocytosisPlatelet countTherapeutic endpointsSafety outcomesAnagrelideEssential thrombocythemiaClinical practicePatientsPlatelet control
2021
Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematology/Oncology Clinics Of North America 2021, 35: 177-189. PMID: 33641862, DOI: 10.1016/j.hoc.2020.11.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsHumansMaleMyeloproliferative DisordersPhiladelphia ChromosomePolycythemia VeraPrimary MyelofibrosisThrombocythemia, Essential
2020
Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia 2020, 35: 1643-1660. PMID: 32868875, PMCID: PMC7917159, DOI: 10.1038/s41375-020-01020-4.Peer-Reviewed Original ResearchConceptsOverall response ratePEG-IFNPolycythemia veraEssential thrombocythemiaHematologic responsePV patientsResponse rateSystematic reviewMeta-regression analysis resultsSafe long-term treatmentPartial hematologic responseSafety of interferonInterferon-alpha therapyLong-term treatmentRandom-effects modelMeta-regression analysisWeb of ScienceTreatment discontinuationCochrane RegistryAdverse eventsComplete responsePartial responsePrimary outcomeThromboembolic complicationsClinical trialsLifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study. International Journal Of Cancer 2020, 147: 948-957. PMID: 31904114, PMCID: PMC8919268, DOI: 10.1002/ijc.32853.Peer-Reviewed Original ResearchConceptsNIH-AARP DietPolycythemia veraMyeloproliferative neoplasmsEssential thrombocythemiaHazard ratioLifestyle factorsCaffeine intakeHealth StudyMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelRisk of PVProportional hazards regression modelsRisk of MPNLarge prospective studiesHazards regression modelsConfidence intervalsPhiladelphia chromosome-negative myeloproliferative neoplasmsMPN riskOverall cohortProspective cohortProspective studyInverse associationRisk factorsPV riskProtective effect
2019
Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. Journal Of The National Comprehensive Cancer Network 2015, 13: 424-34. PMID: 25870379, PMCID: PMC8161684, DOI: 10.6004/jnccn.2015.0058.Peer-Reviewed Original ResearchConceptsMyeloproliferative neoplasmsClassical Philadelphia chromosome-negative myeloproliferative neoplasmsJAK1/JAK2 inhibitor ruxolitinibPrognostic scoring systemHematologists/oncologistsPhiladelphia chromosome-negative myeloproliferative neoplasmsJAK2 inhibitor ruxolitinibQuality of lifeCytoreductive agentsSymptom burdenVascular eventsInhibitor ruxolitinibPolycythemia veraDiagnostic criteriaEssential thrombocythemiaDisease pathogenesisFirst treatmentScoring systemNovel therapeuticsMyelofibrosisCALR mutationsMolecular diagnosisNeoplasms